Bayer chief eyes $2.6B in Xarelto sales

Bayer CEO Werner Wenning predicted that the market for new blood thinners could reach $12 billion to $15 billion, with his company's drug Xarelto--now awaiting U.S. approval--accounting for some $2.6 billion of that. Report